NYSE:NUVBPharmaceuticals
How Investors May Respond To Nuvation Bio (NUVB) Expanding Safusidenib Into a Phase 3 Glioma Trial
In February 2026, Nuvation Bio announced that its global SIGMA (G203) study of safusidenib for IDH1‑mutant astrocytoma had been expanded into a Phase 3 maintenance trial, broadening eligibility to grades 2–4 high‑risk tumors after standard treatment and increasing planned enrollment from 100 to 300 patients across the U.S., Australia and China.
The amended protocol also adds a non‑pivotal, single‑arm cohort in chemotherapy‑ and radiotherapy‑naïve grade 3 IDH1‑mutant oligodendroglioma, which...